Clinical Trial: Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661797) titled 'Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors' on April 08.

Brief Summary: This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Patients With Advanced Solid Tumors

Intervention: DRUG: LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

The dosage of LNF2105 was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.

Recruitment Status: NOT_YET_REC...